Literature DB >> 28475744

Clinical characteristics and associated factors of Japanese patients with adenocarcinoma of the esophagogastric junction: a multicenter clinicoepidemiological study.

K Matsueda1, N Manabe2, N Toshikuni3, Y Sato4, T Watanabe5, H Yamamoto1, K Haruma6.   

Abstract

Gastroesophageal reflux disease-related diseases, such as Barrett's esophagus and adenocarcinoma of the esophagogastric junction (AEGJ), are believed to occur less frequently in Asia than in Western countries. However, the number of reported cases is increasing, yet little is known regarding the epidemiology of AEGJ in Japan. The primary study aim is to investigate the clinicoepidemiological characteristics of AEGJ. The secondary aim is to identify factors associated with it. In the 6.5 years between January 2008 and June 2014, we reviewed 88,199 esophagogastroduodenoscopy (EGD) reports and associated medical records (Study 1). We conducted a case-control study to identify factors associated with AEGJ (Study 2). Control subjects were randomly selected and age and sex matched from among subjects who underwent EGD during medical evaluations. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using an unconditional logistic regression method. During the study period, 83 patients with AEGJ (72 men and 11 women; mean age 68 years) were diagnosed. Six cases were Siewert type I and 77 were type II. The incidence rate of AEGJ was 0.6-1.7/100,000 person-years. Compared with the 101 control subjects, obesity (body mass index ≧ 25 kg/m2; [OR = 2.82; 95% CI: 1.13-7.01]) was associated with AEGJ. The incidence rate of AEGJ is lower in Japan than in Western countries, but associated factors similar to those in Western patients were detected, including obesity, a hiatal hernia, smoking, and the male sex.
© The Authors 2017. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus.All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  adenocarcinoma of the esophagogastric junction; associated factors; epidemiology

Mesh:

Year:  2017        PMID: 28475744     DOI: 10.1093/dote/dox007

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  4 in total

1.  Serum metabolomic profiling for patients with adenocarcinoma of the esophagogastric junction.

Authors:  Yinan Chen; Lei Hu; Hexin Lin; Huangdao Yu; Jun You
Journal:  Metabolomics       Date:  2022-04-19       Impact factor: 4.290

2.  Transthoracic, thoracoabdominal, and transabdominal surgical approaches for gastric cardia adenocarcinomas: a survival evaluation based on a cohort of 7103 patients.

Authors:  Yao Chen; Xue Ke Zhao; Rui Hua Xu; Xin Song; Miao Miao Yang; Fu You Zhou; Ling Ling Lei; Zong Min Fan; Xue Na Han; She Gan Gao; Xian Zeng Wang; Zhi Cai Liu; Ai Li Li; Wen Jun Gao; Jing Feng Hu; Li Guo Zhang; Jin Chang Wei; Fu Lin Jiao; Kan Zhong; Wei Peng Wang; Liu Yu Li; Jia Jia Ji; Xue Min Li; Li Dong Wang
Journal:  World J Surg Oncol       Date:  2022-06-28       Impact factor: 3.253

Review 3.  Current status of surveillance for Barrett's esophagus in Japan and the West.

Authors:  Tomoyuki Koike; Masahiro Saito; Yuki Ohara; Waku Hatta; Atsushi Masamune
Journal:  DEN open       Date:  2022-02-13

4.  The abdominal-transhiatal surgical approach versus the thoracoabdominal surgical approach in Siewert type II adenocarcinoma of the esophagogastric junction: protocol for a multicenter prospective, open, parallel, and randomized controlled trial.

Authors:  Qiying Song; Xiongguang Li; Di Wu; Shuo Li; Tianyu Xie; Yixun Lu; Liyu Zhang; Ziyao Xu; Lu Liu; Xin Guo; Xinxin Wang
Journal:  BMC Cancer       Date:  2022-03-24       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.